Developing Conditionally Active Antibodies Targeting the Tumor Microenvironment ft. John K. Celebi, CEO, Sensei Bio – Xtalks Life Science Podcast Ep. 156

In this episode, Ayesha spoke with John K. Celebi, MBA, President & Chief Executive Officer, Sensei Biotherapeutics, a clinical-stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients.

Sensei Biotherapeutics specializes in creating conditionally active antibodies engineered to operate specifically within the acidic tumor microenvironment, enhancing the immune system’s ability to combat cancer.

John Celebi, MBA, has over 25 years of experience building innovative entrepreneurial biotechnology companies.

Mr. Celebi currently serves on the Board of Directors of Egle Therapeutics SAS, a biotechnology company developing first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.

Mr. Celebi received an MBA from Carnegie Mellon University and a BS in biophysics from the University of California, San Diego.

Tune into the episode to learn more about Sensei Bio’s mission and therapeutic approach.

The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

If you want your company to be featured on Xtalks.com, please email [email protected].